Children's Oncology Group's 2013 blueprint for research: Renal tumors

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 994-1000

  Dome, Jeffrey S ^a   Fernandez, Conrad V ^b   Mullen, Elizabeth A ^c   Kalapurakal, John A ^d   Geller, James I ^e   Huff, Vicki ^f   Gratias, Eric J ^g   Dix, David B ^h   Ehrlich, Peter F ⁱ   Khanna, Geetika ^j   Malogolowkin, Marcio H ^k   Anderson, James R ^l   Naranjo, Arlene ^m   Perlman, Elizabeth J ⁿ  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b IWK HEALTH CENTRE   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^h BC CHILDREN S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Children's Hospital of Wisconsin   (United States)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^m UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Clear cell sarcoma; Malignant rhabdoid tumor; Renal cell carcinoma; Wilms tumor

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ANAPLASTIC WILMS TUMOR; CANCER GENETICS; CANCER INCIDENCE; CANCER PROGNOSIS; CHILDHOOD CANCER; CHROMOSOME 1Q; CLEAR CELL SARCOMA; CLEAR CELL SARCOMA OF THE KIDNEY; EPIGENETICS; FAVORABLE HISTOLOGY WILMS TUMOR; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALIGNANT RHABDOID TUMOR; MEDICAL RESEARCH; NEPHROBLASTOMA; PRIORITY JOURNAL; REVIEW;

CHEMOTHERAPY, ADJUVANT; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY; RESEARCH;

EID: 84876430490     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24419     Document Type: Review

References (62)

1. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: The experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002; 24: 192-198.
2. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008; 50: 236-241.
3. Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. Eur J Cancer 4: 2012.
4. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study. J Clin Oncol 2006; 24: 2352-2358.
5. Graf N, van Tinteren H, Bergeron C, et al. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01. Eur J Cancer 2012; 48: 3240-3248.
6. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: Age at diagnosis as a prognostic factor. J Clin Oncol 2005; 23: 7641-7645.
7. van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatr Blood Cancer 2011; 56: 733-737.
8. Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer 2004; 101: 1575-1583.
9. Indolfi P, Terenziani M, Casale F, et al. Renal cell carcinoma in children: A clinicopathologic study. J Clin Oncol 2003; 21: 530-535.
10. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011; 57: 1210-1216.
11. Howlader NNA, Krapcho M, Neyman N, et al., SEER Cancer Statistics Review, 1975-2008, 2011; http://seer.cancer.gov/csr/1975_2008/csr/1975_2008/
12. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23: 7312-7321.
13. Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchronous bilateral Wilms tumor: A report from the National Wilms Tumor Study Group. Ann Surg 2011; 253: 1004-1010.
14. Seibel NL, Sun J, Anderson JR, et al. Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS). J Clin Oncol 2006; 24: 502S.
15. Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: An international collaborative study. Int J Cancer 2009; 127: 657-666.
16. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19: 1926-1934.
17. Green DM, Lange JM, Peabody EM, et al. Pregnancy outcome after treatment for Wilms tumor: A report from the national Wilms tumor long-term follow-up study. J Clin Oncol 2010; 28: 2824-2830.
18. Steenman MJC, Rainier S, Dobry CJ, et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genetics 1994; 7: 433-439.
19. Fukuzawa R, Breslow NE, Morison IM, et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 2004; 363: 446-451.
20. Hu Q, Gao F, Tian W, et al. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 2010; 121: 174-183.
21. Shuman CBJ, Smith AC, Weksberg R. Beckwith-Wiedemann syndrome. In: RABT Pagon, CR Dolan, editors. GeneReviews (Internet). Seattle: University of Washington; 2010.
22. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008; 47: 461-470.
23. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP). Pediatr Blood Cancer 2010; 55: 26-34.
24. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005; 11: 6950-6958.
25. Carol H, Lock R, Houghton PJ, et al. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 1255-1263.
26. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-206.
27. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74-79.
28. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2010; 56: 7-15.
29. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009; 8: 412-416.
30. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin. Lab Med 2005; 25: 363-378.
31. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67: 919-929.
32. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Cancer 2012; 118: 5894-5902.
33. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC Network. Ann Oncol 2010; 21: 1834-1838.
34. Parikh J, Coleman T, Messias N, et al. Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: A case report and review of literature. Rare Tumors 2009; 1: e53.
35. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116: 5219-5225.
36. Malouf GG, Camparo P, Molinie V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: Clinical features, biological behavior and prognostic factors. J Urol 2011; 185: 24-29.
37. Liu YC, Chang PM, Liu CY, et al. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Jpn J Clin Oncol 2011; 41: 1277-1281.
38. Dome JS, Bockhold CA, Li SM, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005; 23: 9138-9145.
39. Huang CC, Gadd S, Breslow N, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 2009; 15: 1770-1778.
40. Khanna G, Rosen N, Anderson JR, et al. Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 58: 551-555.
41. Gadd S, Huff V, Huang CC, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: A Children's Oncology Group Study. Neoplasia 2012; 14: 742-756.
42. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 2001; 19: 3719-3724.
43. Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010; 251: 555-558.
44. Sredni ST, Gadd S, Huang CC, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 2009; 15: 6800-6809.
45. Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: A children's oncology group study. J Clin Oncol 2011; 29: 698-703.
46. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210: 49-58.
47. Natrajan R, Little SE, Sodha N, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2007; 211: 52-59.
48. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001; 158: 393-398.
49. Lu YJ, Hing S, Williams R, et al. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002; 360: 385-386.
50. Spreafico F, Pritchard Jones K, Malogolowkin MH, et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Ther 2009; 9: 1807-1815.
51. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007; 48: 493-499.
52. Reinhard H, Schmidt A, Furtwangler R, et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol Rep 2008; 20: 463-467.
53. Breslow NE, Ou SS, Beckwith JB, et al. Doxorubicin for favorable histology, Stage II-III Wilms tumor: Results from the National Wilms Tumor Studies. Cancer 2004; 101: 1072-1080.
54. Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 2004; 22: 1366-1372.
55. Pritchard Jones K, Graf N, Bergeron C, et al. Doxorubicin can be safely omitted from the treatment of Stage II/III intermediate risk histology Wilms tumour: Results of the SIOP 2001 randomized trial. Pediatr Blood Cancer 2011; 57: 741.
56. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003; 57: 875-890.
57. Schwarz M, Alber M, Lebesque JV, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int.J Radiat Oncol Biol Phys 2005; 62: 561-570.
58. Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: Results from the National Wilms tumor study group and the United States Renal Data System. J Urol 2005; 174: 1972-1975.
59. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Stat Med 1995; 14: 231-246.
60. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27-36.
61. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011; 9: 199-207.
62. Metzger ML, Stewart CF, Freeman BB III, et al. Topotecan is active against Wilms' tumor: Results of a multi-institutional phase II study. J Clin Oncol 2007; 25: 3130-3136.